Annual FCF
-$338.69 M
-$17.07 M-5.31%
December 31, 2024
Summary
- As of February 26, 2025, TVTX annual free cash flow is -$338.69 million, with the most recent change of -$17.07 million (-5.31%) on December 31, 2024.
- During the last 3 years, TVTX annual FCF has fallen by -$299.74 million (-769.70%).
Performance
TVTX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$45.28 M
+$5.42 M+10.69%
December 1, 2024
Summary
- As of February 26, 2025, TVTX quarterly free cash flow is -$45.28 million, with the most recent change of +$5.42 million (+10.69%) on December 1, 2024.
- Over the past year, TVTX quarterly FCF has increased by +$30.05 million (+39.89%).
- TVTX quarterly FCF is now -269.66% below its all-time high of $26.69 million, reached on September 30, 2021.
Performance
TVTX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$338.69 M
+$30.05 M+8.15%
December 1, 2024
Summary
- As of February 26, 2025, TVTX TTM free cash flow is -$338.69 million, with the most recent change of +$30.05 million (+8.15%) on December 1, 2024.
- Over the past year, TVTX TTM FCF has dropped by -$17.07 million (-5.31%).
Performance
TVTX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
TVTX Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.3% | +39.9% | -5.3% |
| 3 y3 years | -769.7% | +39.9% | -5.3% |
| 5 y5 years | -359.1% | +39.9% | -5.3% |
TVTX Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -769.7% | at low | -41.2% | +63.9% | -769.7% | +11.4% |
| 5 y | 5-year | -769.7% | at low | -269.7% | +63.9% | -769.7% | +11.4% |
| alltime | all time | <-9999.0% | at low | -269.7% | +63.9% | <-9999.0% | +11.4% |
Travere Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$338.69 M(+5.3%) | - | - |
| Dec 2024 | - | -$45.28 M(-10.7%) | -$338.69 M(-8.2%) |
| Sep 2024 | - | -$50.70 M(-56.8%) | -$368.74 M(-3.5%) |
| Jun 2024 | - | -$117.24 M(-6.6%) | -$382.10 M(+13.0%) |
| Mar 2024 | - | -$125.47 M(+66.6%) | -$338.00 M(+5.1%) |
| Dec 2023 | -$321.61 M(+49.8%) | -$75.33 M(+17.6%) | -$321.61 M(+5.5%) |
| Sep 2023 | - | -$64.06 M(-12.4%) | -$304.92 M(+5.8%) |
| Jun 2023 | - | -$73.13 M(-33.0%) | -$288.17 M(+9.5%) |
| Mar 2023 | - | -$109.08 M(+86.0%) | -$263.15 M(+22.6%) |
| Dec 2022 | -$214.66 M(+451.2%) | -$58.65 M(+24.0%) | -$214.66 M(+14.1%) |
| Sep 2022 | - | -$47.31 M(-1.7%) | -$188.09 M(+64.9%) |
| Jun 2022 | - | -$48.12 M(-20.6%) | -$114.09 M(+78.9%) |
| Mar 2022 | - | -$60.59 M(+88.9%) | -$63.79 M(+63.8%) |
| Dec 2021 | -$38.94 M(-76.0%) | -$32.08 M(-220.2%) | -$38.94 M(-68.7%) |
| Sep 2021 | - | $26.69 M(+1119.2%) | -$124.62 M(-17.7%) |
| Jun 2021 | - | $2.19 M(-106.1%) | -$151.49 M(-7.9%) |
| Mar 2021 | - | -$35.74 M(-69.6%) | -$164.56 M(+1.2%) |
| Dec 2020 | -$162.59 M(+120.4%) | -$117.75 M(>+9900.0%) | -$162.59 M(+205.0%) |
| Sep 2020 | - | -$180.00 K(-98.3%) | -$53.31 M(-25.4%) |
| Jun 2020 | - | -$10.89 M(-67.8%) | -$71.47 M(-14.0%) |
| Mar 2020 | - | -$33.77 M(+298.6%) | -$83.08 M(+12.6%) |
| Dec 2019 | -$73.78 M(+65.2%) | -$8.47 M(-53.8%) | -$73.78 M(+1.4%) |
| Sep 2019 | - | -$18.34 M(-18.5%) | -$72.74 M(+17.0%) |
| Jun 2019 | - | -$22.50 M(-8.1%) | -$62.14 M(+34.7%) |
| Mar 2019 | - | -$24.47 M(+229.3%) | -$46.14 M(+3.3%) |
| Dec 2018 | -$44.66 M(+576.0%) | -$7.43 M(-4.0%) | -$44.66 M(+8.9%) |
| Sep 2018 | - | -$7.74 M(+19.2%) | -$41.02 M(+33.1%) |
| Jun 2018 | - | -$6.49 M(-71.8%) | -$30.82 M(+40.9%) |
| Mar 2018 | - | -$22.99 M(+506.0%) | -$21.87 M(+231.1%) |
| Dec 2017 | -$6.61 M | -$3.79 M(-254.0%) | -$6.61 M(-57.5%) |
| Sep 2017 | - | $2.46 M(+0.7%) | -$15.54 M(-3.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | $2.45 M(-131.7%) | -$16.16 M(-4.5%) |
| Mar 2017 | - | -$7.72 M(-39.3%) | -$16.92 M(+10.1%) |
| Dec 2016 | -$15.37 M(+82.5%) | -$12.72 M(-791.1%) | -$15.37 M(+94.1%) |
| Sep 2016 | - | $1.84 M(+9.3%) | -$7.92 M(-32.9%) |
| Jun 2016 | - | $1.68 M(-127.3%) | -$11.80 M(+68.1%) |
| Mar 2016 | - | -$6.17 M(+16.9%) | -$7.02 M(-16.6%) |
| Dec 2015 | -$8.42 M(-83.1%) | -$5.28 M(+158.5%) | -$8.42 M(-31.7%) |
| Sep 2015 | - | -$2.04 M(-131.6%) | -$12.32 M(-52.5%) |
| Jun 2015 | - | $6.46 M(-185.4%) | -$25.94 M(-45.2%) |
| Mar 2015 | - | -$7.57 M(-17.5%) | -$47.35 M(-5.0%) |
| Dec 2014 | -$49.81 M(+115.3%) | -$9.18 M(-41.4%) | -$49.81 M(-8.3%) |
| Sep 2014 | - | -$15.66 M(+4.8%) | -$54.31 M(+31.4%) |
| Jun 2014 | - | -$14.95 M(+49.0%) | -$41.32 M(+44.5%) |
| Mar 2014 | - | -$10.03 M(-26.6%) | -$28.59 M(+23.5%) |
| Dec 2013 | -$23.14 M(+488.8%) | -$13.67 M(+412.3%) | -$23.14 M(+144.3%) |
| Sep 2013 | - | -$2.67 M(+20.3%) | -$9.47 M(+39.2%) |
| Jun 2013 | - | -$2.22 M(-51.7%) | -$6.80 M(+48.3%) |
| Mar 2013 | - | -$4.59 M(<-9900.0%) | -$4.59 M(<-9900.0%) |
| Dec 2012 | -$3.93 M(<-9900.0%) | - | - |
| Nov 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| Aug 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| May 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| Feb 2012 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Feb 2012 | $0.00(-100.0%) | - | - |
| Nov 2011 | - | $0.00(0.0%) | -$600.00(-14.3%) |
| Aug 2011 | - | $0.00(0.0%) | -$700.00(0.0%) |
| May 2011 | - | $0.00(-100.0%) | -$700.00(0.0%) |
| Feb 2011 | -$700.00 | -$600.00(+500.0%) | -$700.00(+600.0%) |
| Nov 2010 | - | -$100.00(<-9900.0%) | -$100.00(<-9900.0%) |
| Aug 2010 | - | $0.00(0.0%) | $0.00(0.0%) |
| May 2010 | - | $0.00 | $0.00 |
FAQ
- What is Travere Therapeutics annual free cash flow?
- What is the all time high annual FCF for Travere Therapeutics?
- What is Travere Therapeutics annual FCF year-on-year change?
- What is Travere Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Travere Therapeutics?
- What is Travere Therapeutics quarterly FCF year-on-year change?
- What is Travere Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Travere Therapeutics?
- What is Travere Therapeutics TTM FCF year-on-year change?
What is Travere Therapeutics annual free cash flow?
The current annual FCF of TVTX is -$338.69 M
What is the all time high annual FCF for Travere Therapeutics?
Travere Therapeutics all-time high annual free cash flow is $0.00
What is Travere Therapeutics annual FCF year-on-year change?
Over the past year, TVTX annual free cash flow has changed by -$17.07 M (-5.31%)
What is Travere Therapeutics quarterly free cash flow?
The current quarterly FCF of TVTX is -$45.28 M
What is the all time high quarterly FCF for Travere Therapeutics?
Travere Therapeutics all-time high quarterly free cash flow is $26.69 M
What is Travere Therapeutics quarterly FCF year-on-year change?
Over the past year, TVTX quarterly free cash flow has changed by +$30.05 M (+39.89%)
What is Travere Therapeutics TTM free cash flow?
The current TTM FCF of TVTX is -$338.69 M
What is the all time high TTM FCF for Travere Therapeutics?
Travere Therapeutics all-time high TTM free cash flow is $0.00
What is Travere Therapeutics TTM FCF year-on-year change?
Over the past year, TVTX TTM free cash flow has changed by -$17.07 M (-5.31%)